small molecule

SOOLANTRA

IVERMECTIN

Loss of exclusivityMarch 2034latest FDA-listed patent expiry
CompanyGALDERMA LABORATORIES LP

Drug detail

Brand nameSOOLANTRA
Active ingredientIVERMECTIN
Strength1%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2014
Marketing statusRX

Listed patents

PatentExpiresType
9233118March 2034use U-1631
9089587March 2034use U-1631
9233117March 2034use U-1631
9782425March 2034use U-1631
10206939March 2034use U-1631

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SOOLANTRA patent cliff — loss of exclusivity March 2034 | CliffBio